Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.

被引：2

作者：

Fan, Bin

Goyal, Lipika

Lowery, Maeve Aine

Pandya, Shuchi Sumant

Manyak, Erika

Le, Kha

Jiang, Liewen

Auer, Julia

Dai, David

机构：

[1] Agios Pharmaceut Inc, Cambridge, MA USA

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Harvard Med Sch, Boston, MA 02115 USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Weill Cornell Med Coll, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.4082

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4082

引用

页数：6

共 50 条

[21] Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.
Roboz, Gail J.
Dinardo, Courtney Denton
Stein, Eytan M.
de Botton, Stephane
Mims, Alice S.
Prince, Gabrielle T.
Altman, Jessica K.
Arellano, Martha Lucia
Erba, Harry Paul
Pollyea, Daniel Aaron
Stein, Anthony Selwyn
Watts, Justin M.
Fathi, Amir Tahmasb
Kantarjian, Hagop M.
Tallman, Martin S.
Fan, Bin
Liu, Hua
Wu, Bin
Attar, Eyal C.
Stone, Richard M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[22] Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study
DiNardo, Courtney D.
Watts, Justin M.
Stein, Eytan M.
De Botton, Stephane
Fathi, Amir T.
Prince, Gabrielle T.
Stein, Anthony S.
Foran, James M.
Stone, Richard M.
Patel, Prapti A.
Tallman, Martin S.
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Dai, David
Fan, Bin
Yen, Katharine E.
Kapsalis, Stephanie M.
Hickman, Denice
Agresta, Samuel V.
Liu, Hua
Wu, Bin
Attar, Eyal C.
Kantarjian, Hagop M.
BLOOD, 2018, 132
[23] Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
DiNardo, Courtney D.
De Botton, Stephane
Stein, Eytan M.
Roboz, Gail J.
Mims, Alice S.
Pollyea, Daniel A.
Swords, Ronan T.
Altman, Jessica K.
Collins, Robert H.
Mannis, Gabriel N.
Uy, Geoffrey L.
Donnellan, Will
Pigneux, Arnaud
Fathi, Amir T.
Stein, Anthony S.
Erba, Harry P.
Prince, Gabrielle T.
Foran, James M.
Traer, Elie
Stuart, Robert K.
Arellano, Martha L.
Slack, James L.
Sekeres, Mikkael A.
Yen, Katharine
Kapsalis, Stephanie M.
Liu, Hua
Goldwasser, Meredith
Agresta, Sam
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
BLOOD, 2017, 130
[24] A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT, IDH1-MUTANT, LOW-GRADE GLIOMA: RESULTS FROM COHORT 1
Mellinghoff, I. K.
Wen, P. Y.
Taylor, J. W.
Maher, E. A.
Arrillaga-Romany, I.
Peters, K. B.
Le, K.
Tai, F.
Steelman, L.
Cloughesy, T. F.
NEURO-ONCOLOGY, 2019, 21 : 2 - 2
[25] A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA
Mellinghoff, Ingo
Maher, Elizabeth
Wen, Patrick
Cloughesy, Timothy
Peters, Katherine
Choi, Changho
Ellingson, Benjamin
Lin, Alexander
Li, Yan
Soher, Brian
Young, Robert
Steelman, Lori
Le, Kha
Yin, Feng
Wu, Bin
Lu, Min
Zhang, Yanwei
Nicolay, Brandon
Schoenfeld, Steven
Yen, Katharine
Pandya, Shuchi
Clarke, Jennifer
NEURO-ONCOLOGY, 2018, 20 : 234 - 234
[26] Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma
Mellinghoff, Ingo K.
Penas-Prado, Marta
Peters, Katherine B.
Cloughesy, Timothy Francis
Burris, Howard A.
Maher, Elizabeth A.
Janku, Filip
Cote, Gregory Michael
De La Fuente, Macarena Ines
Clarke, Jennifer
Steelman, Lori
Le, Kha
Zhang, Yanwei
Sonderfan, Alison
Hummel, Diana
Schoenfeld, Steven
Yen, Katharine
Pandya, Shuchi Sumant
Wen, Patrick Y.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors.
Ricart, A. D.
Cooney, M.
Sarantopoulos, J.
Brell, J.
Locke, K. W.
Gammans, R. E.
Medina, G.
Zambito, A.
Tolcher, A. W.
Remick, S. C.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 144S - 144S
[28] Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors
Tolcher, Anthony W.
Siu, Lillian L.
Cabanas, Elena Garralda
Boni, Valentina
Garcia, Enrique Sanz
Fuentes-Antras, Jesus
Saavedra, Omar
Coenen-Stass, Anna
Locatelli, Giuseppe
Vagge, Deepthi S.
Gunhan, Burak Kursad
Pennock, Gregory K.
Mukker, Jatinder Kaur
Gounaris, Ioannis
Yap, Timothy A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[29] Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
DiNardo, Courtney D.
Stein, Eytan M.
de Botton, Stephane
Roboz, Gail J.
Altman, Jessica K.
Mims, Alice S.
Swords, Ronan
Collins, Robert H.
Mannis, Gabriel N.
Pollyea, Daniel A.
Donnellan, Will
Fathi, Amir T.
Pigneux, Arnaud
Erba, Harry P.
Prince, Gabrielle T.
Stein, Anthony S.
Uy, Geoffrey L.
Foran, James M.
Traer, Elie
Stuart, Robert K.
Arellano, Martha L.
Slack, James L.
Sekeres, Mikkael A.
Willekens, Christophe
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Yang, Hua
Dai, David
Fan, Bin
Goldwasser, Meredith
Liu, Hua
Agresta, Sam
Wu, Bin
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S204 - S205
[30] PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) EVALUATION OF AG-221, A POTENT MUTANT IDH2 INHIBITOR, FROM A PHASE 1 TRIAL OF PATIENTS WITH IDH2-MUTATION POSITIVE HEMATOLOGIC MALIGNANCIES
Fan, B.
Chen, Y.
Wang, F.
Yen, K.
Utley, L.
Almon, C.
Straley, K.
Attar, E.
Bowden, C.
Biller, S.
Agresta, S.
Yang, H.
HAEMATOLOGICA, 2015, 100 : 379 - 379

← 1 2 3 4 5 →